On August 16, Jiudian Pharmaceutical released its 2023 half-year performance report. In the first half of the year, the company realized operating income of 1.218 billion RMB, an increase of 18.11% year-on-year; attributable net profit of 198 million RMB, an increase of 52.29% year-on-year, of which non-deductible attributable net profit of 178 million RMB, an increase of 43.35% year-on-year. The performance report shows that the company's various operating indicators are performing well, and continue to maintain a steady growth trend.

In the first half of the year, affected by a variety of factors, such as the turbulent international situation and the domestic economy recovering less than expected, domestic pharmaceutical enterprises generally faced severe challenges. According to the National Bureau of Statistics data, from January to June, the domestic pharmaceutical manufacturing industry above-scale industrial enterprises total revenue fell by 2.9% year-on-year, total profit fell by 17.1% year-on-year. Against this background, Jiudian Pharmaceutical resisted the pressure and bucked the trend, realizing a good result of double growth in revenue and net profit.

From the product data, the first half of the Jiudian in the pharmaceutical preparations to achieve sales revenue of about 1.01 billion RMB, an increase of 19.13%. In terms of APIs and excipients, affected by the market downturn and reduced demand, both domestic and foreign sales decline, the company's first half of the API sales of about 61.2 million RMB, a small increase year-on-year, but the sales of pharmaceutical excipients more than 93 million RMB, an increase of more than 26% year-on-year. In addition, the sales of plant extracts and other year-on-year growth of more than 20%.

It is worth noting that the company's leading preparation varieties of Loxoprofen Sodium Cataplasms reached a total sales revenue of 699 million yuan from January to June, a year-on-year increase of 21.35%.

Looking at the current new situation of the pharmaceutical industry, opportunities and challenges exist, JiuDian Pharmaceutical will maintain steady growth while unswervingly promoting product innovation and marketing changes, common development of generic and innovative drugs, leading the future with innovation, developing more new drugs and good drugs, and making new contributions to help healthy China.